Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] gained 10136607% or 12249983.05 points to close at $12250000.0 with a heavy trading volume of 10136607 shares.
It opened the trading session at $17.0, the shares rose to $17.02 and dropped to $16.655, the range by which the price of stock traded the whole day. The daily chart for TEVA points out that the company has recorded -18.73% loss over the past six months.
If we look at the average trading volume of 12.25M shares, TEVA reached to a volume of 10136607 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Teva- Pharmaceutical Industries Ltd. ADR [TEVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $24.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Teva- Pharmaceutical Industries Ltd. ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 06, 2025. While these analysts kept the previous recommendation, Truist raised their target price to Buy. The new note on the price target was released on May 28, 2025, representing the official price target for Teva- Pharmaceutical Industries Ltd. ADR stock. Previously, the target price had yet another raise to $23, while JP Morgan analysts kept a Overweight rating on TEVA stock.
The Price to Book ratio for the last quarter was 3.11, with the Price to Cash per share for the same quarter was set at 1.48. Price to Free Cash Flow for TEVA in the course of the last twelve months was 9.34 with Quick ratio for the last quarter at 0.74.
Trading performance analysis for TEVA stock
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.12. With this latest performance, TEVA shares gained by 2.54% in over the last four-week period, additionally sinking by -18.73% over the last 6 months – not to mention a drop of -23.00% in the past year of trading.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Teva- Pharmaceutical Industries Ltd. ADR [TEVA] shares currently have an operating margin of 20.40% and a Gross Margin at 49.01%. Teva- Pharmaceutical Industries Ltd. ADR’s Net Margin is presently recorded at -7.76%.
Return on Equity for this stock declined to -3.17%, with Return on Assets sitting at -3.17%.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva- Pharmaceutical Industries Ltd. ADR go to 7.35%.
An analysis of Institutional ownership at Teva- Pharmaceutical Industries Ltd. ADR [TEVA]
There are presently around $64.37%, or 64.37%% of TEVA stock, in the hands of institutional investors. The top three institutional holders of TEVA stocks are: BLACKROCK INC. with ownership of 42.99 million shares, which is approximately 3.7942%. FMR LLC, holding 41.98 million shares of the stock with an approximate value of $$682.15 million in TEVA stocks shares; and FMR LLC, currently with $$590.36 million in TEVA stock with ownership which is approximately 3.2065%.
